GB9814892D0 - Treatment of celiac disease - Google Patents

Treatment of celiac disease

Info

Publication number
GB9814892D0
GB9814892D0 GBGB9814892.7A GB9814892A GB9814892D0 GB 9814892 D0 GB9814892 D0 GB 9814892D0 GB 9814892 A GB9814892 A GB 9814892A GB 9814892 D0 GB9814892 D0 GB 9814892D0
Authority
GB
United Kingdom
Prior art keywords
treatment
celiac disease
antagonists
interfere
muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9814892.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Kennedy Institute of Rheumotology
Mathilda and Terence Kennedy Institute of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology, Mathilda and Terence Kennedy Institute of Rheumatology filed Critical Kennedy Institute of Rheumotology
Priority to GBGB9814892.7A priority Critical patent/GB9814892D0/en
Publication of GB9814892D0 publication Critical patent/GB9814892D0/en
Priority to CA002333923A priority patent/CA2333923A1/en
Priority to JP2000558841A priority patent/JP2002520294A/en
Priority to PCT/GB1999/002201 priority patent/WO2000002582A2/en
Priority to EP99933001A priority patent/EP1096949A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the treatment of inflammatory bowel diseases, such as celiac disease with interleukin-15 (IL-15) antagonists. Preferably the antagonists are muteins of IL-15, antibodies against IL-15 or IL-15 molecules bound to chemical groups that interfere with the ability of IL-15 to effect a signal transduction through either the beta or gamma -subunit of the IL-15 receptor complex, but which do not interfere with IL-15 binding to IL-15R alpha .
GBGB9814892.7A 1998-07-10 1998-07-10 Treatment of celiac disease Ceased GB9814892D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9814892.7A GB9814892D0 (en) 1998-07-10 1998-07-10 Treatment of celiac disease
CA002333923A CA2333923A1 (en) 1998-07-10 1999-07-09 Treatment of celiac disease with interleukin-15 antagonists
JP2000558841A JP2002520294A (en) 1998-07-10 1999-07-09 Treatment of celiac disease with interleukin-15 antagonists
PCT/GB1999/002201 WO2000002582A2 (en) 1998-07-10 1999-07-09 Treatment of celiac disease with interleukin-15 antagonists
EP99933001A EP1096949A2 (en) 1998-07-10 1999-07-09 Treatment of celiac disease with interleukin-15 antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9814892.7A GB9814892D0 (en) 1998-07-10 1998-07-10 Treatment of celiac disease

Publications (1)

Publication Number Publication Date
GB9814892D0 true GB9814892D0 (en) 1998-09-09

Family

ID=10835232

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9814892.7A Ceased GB9814892D0 (en) 1998-07-10 1998-07-10 Treatment of celiac disease

Country Status (5)

Country Link
EP (1) EP1096949A2 (en)
JP (1) JP2002520294A (en)
CA (1) CA2333923A1 (en)
GB (1) GB9814892D0 (en)
WO (1) WO2000002582A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
RS51829B (en) * 2001-08-23 2012-02-29 Genmab A/S. Human antibodies specific for interleukin 15 (il-15)
CU23093A1 (en) 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech VACCINE COMPOSITION INCLUDING INTERLEUCINE-15 (IL-15)
EA015897B1 (en) * 2003-02-26 2011-12-30 Генмаб А/С Use of human monoclonal antibody to il-15 comprising a composition and medical preparation (variants), composition and medical preparation containing them
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
WO2005099753A1 (en) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
CU23472A1 (en) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech ANTAGONIST PEPTIDE OF INTERLEUCINE-15
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
US20180002417A1 (en) * 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
WO2018041989A1 (en) * 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
CA2252557A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15

Also Published As

Publication number Publication date
JP2002520294A (en) 2002-07-09
EP1096949A2 (en) 2001-05-09
WO2000002582A2 (en) 2000-01-20
CA2333923A1 (en) 2000-01-20
WO2000002582A3 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
GB9814892D0 (en) Treatment of celiac disease
TR199900318T2 (en) IL-8 receptor antagonists.
TR199901710T2 (en) IL-8 receptor antagonists.
HUP0203567A2 (en) April receptor (bcma) and uses thereof
EP1017713A4 (en) CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
EP1401870A4 (en) Antibodies against tumor necrosis factor delta (april)
FI963101A (en) Use of anti-TNF antibodies as drugs for the treatment of diseases in which serum interleukin-6 levels are elevated
DE60329030D1 (en) Melanocortin receptor MODULATORS
TR200100267T2 (en) Substituted anilide compositions and methods.
GB9806530D0 (en) Inflammatory mediator
CY1112101T1 (en) Neurotrophic factors
HUP0401591A2 (en) Novel receptor nucleic acids and polypeptides
EP1383919A4 (en) Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
MXPA05011409A (en) Compositions and methods for the therapy of inflammatory bowel disease.
TR200002896T2 (en) Calcilitic Compositions
BG108427A (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diaryl pyrimidines as crf1 receptor modulators
DE69935782D1 (en) BREAST CANCER RESISTANT PROTEIN (BCRP) AND FOR THIS ENCODING DNA
PT977716E (en) USE OF ALCOHOLS AS ADDITIVES FOR GRILLS AND / OR MORTARS
ZA200107906B (en) Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor.
MY133845A (en) Il-8 receptor antagonists
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
NZ514696A (en) IL-8 receptor antagonists
TR200103448T2 (en) IL-8 receptor antagonists.
DE69626387D1 (en) ANTAGONISTS OF HUMANEM INTERLEUKIN-6, WHICH ARE UNABLE TO BIND WITH GP 130 AND THEIR USE IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS
ATE474047T1 (en) NUCLEIC ACID MOLECULES ENCODING THE ALPHA CHAIN OF THE HORSE FC EPSILON RECEPTOR, CORRESPONDING PROTEINS AND THEIR USES

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)